Sekce: Daily overview

Selection from Decision-Making Practice - 16

Questions Surrounding Reimbursement for Off-Label Indications
Pharmeca a.s. 06/25/2025
Sekce: Daily overview

Selection from Decision-Making Practice - 15

The Importance of Therapeutic Interchangeability for Ensuring Full Reimbursement Within an Annex No. 2 Group Under the Act on Public Health Insurance
Pharmeca a.s. 06/18/2025
Sekce: Daily overview

Selection from Decision-Making Practice - 14

Confidential Agreements May Not Be Considered in the Administrative Procedure
Pharmeca a.s. 06/13/2025
Sekce: Daily overview

Selection from Decision-Making Practice - 13

Assessment of Essentially Therapeutically Interchangeable Medicines
Pharmeca a.s. 06/04/2025
Sekce: Daily overview

Selection from Decision-Making Practice - 12

Statement on Unacceptable Budget Impact
Pharmeca a.s. 05/28/2025
Sekce: Daily overview

Selection from Decision-Making Practice - 11

SÚKL Took City Court Ruling into Account
Pharmeca a.s. 05/21/2025
Sekce: Daily overview

Selection from Decision-Making Practice - 10

The Ministry of Health confirmed the rejection of the application due to overlapping indications.
Pharmeca a.s. 05/14/2025
Sekce: Daily overview

Selection from Decision-Making Practice - 9

SÚKL Launches First Ex Officio Review of VILP Reimbursement
Pharmeca a.s. 05/09/2025